The invention relates to a self-microemulsifying drug delivery system ("SMEDDS") of mitotane with enhanced bioavailability. More particularly the invention provides a mitotane oily formulation comprising propylene glycol monocaprylate (10 to 30% w/w) propylene glycol dicaprate (20 to 60% w/w) and polyoxyethylenesorbitanne monooleate (10 to 30% w/w).

The invention relates to a self-microemulsifying drug delivery system (SMEDDS) of mitotane with enhanced bioavailability. More particularly the invention provides a mitotane oily formulation comprising propylene glycol monocaprylate (10 to 30% w/w) propylene glycol dicaprate (20 to 60% w/w) and polyoxyethylenesorbitanne monooleate (10 to 30% w/w).

The invention relates to a self-microemulsifying drug delivery system (SMEDDS) of mitotane, with enhanced bioavailability. More particularly the invention provides a mitotane oily formulation comprising propylene glycol monocaprylate (10 to 30% w/w), propylene glycol dicaprate (20 to 60% w/w) and polyoxyethylenesorbitanne monooleate (10 to 30% w/w).

The invention relates to a self-microemulsifying drug delivery system ("SMEDDS") of mitotane with enhanced bioavailability.More particularly the invention provides a mitotane oily formulation comprising propylene glycol monocaprylate (10 to 30% w/w) propylene glycol dicaprate (20 to 60% w/w) and polyoxyethylenesorbitanne monooleate (10 to 30% w/w).(From EP2255786 A1)

The present invention provides a compound of formula (30) for use in the treatment of a 5a-reductase-mediated condition in a human or animal: where X1 and X2 are independently selected from H, halogen, substutituted or unsubstituted amino, hydroxyl, C1-C6 alkoxy, substutituted or unsubstituted carboxylate, substituted or unsubstituted C1-C6 alkyl, substutituted or unsubstituted C2-C6 alkenyl, substutituted or unsubstituted C2-C6 alkynyl, or substutituted or unsubstituted aryl

The invention relates to a self-microemulsifying drug delivery system ("SMEDDS") of mitotane with enhanced bioavailability. More particularly the invention provides a mitotane oily formulation comprising propylene glycol monocaprylate (10 to 30% w/w) propylene glycol dicaprate (20 to 60% w/w) and polyoxyethylenesorbitanne monooleate (10 to 30% w/w).

In the present invention there is disclosed a pharmaceutical composition containing cyclopeptide cyclo-(Arg-Gly-Asp-D-Phe-NMe-Val) and/or a physiologically acceptable salt thereof and at least one chemotherapeutic agent and/or physiologically acceptable salts thereof being selected from the group consisting of a) alkylating agents selected from a group consisting of busulfan carboplatin carmustine cisplatin cyclophosphamide dacarbazine ifosfamide and lomustine b) antibiotics selected from a grou...

The invention relates to a self-microemulsifying drug delivery system ("SMEDDS") of mitotane, with enhanced bioavailability. More particularly the invention provides a mitotane oily formulation comprising propylene glycol monocaprylate (10 to 30% w/w), propylene glycol dicaprate (20 to 60% w/w) and polyoxyethylenesorbitanne monooleate (10 to 30% w/w).

The invention relates to a self-microemulsifying drug delivery system ("SMEDDS") of mitotane, with enhanced bioavailability. More particularly the invention provides a mitotane oily formulation comprising propylene glycol monocaprylate (10 to 30% w/w), propylene glycol dicaprate (20 to 60% w/w) and polyoxyethylenesorbitanne monooleate (10 to 30% w/w).